Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 29, 2014
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinaseShinji Yamazaki, Justine L Lam, Helen Y Zou, et al.
ACS Chemical Biology|February 28, 2013
Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domainJames Solowiej, Jeffrey H Chen, Helen Y Zou, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 31, 2014
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1Shinji Yamazaki, Justine L Lam, Helen Y Zou, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 2, 2011
Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse modelsShinji Yamazaki, Paolo Vicini, Zhongzhou Shen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 3, 2008
Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse modelsShinji Yamazaki, Judith Skaptason, David Romero, et al.
Molecular Cancer Therapeutics|December 20, 2007
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaJames G Christensen, Helen Y Zou, Maria E Arango, et al.
Biochemistry|May 23, 2009
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitorsSergei L Timofeevski, Michele A McTigue, Kevin Ryan, et al.
Cancer Discovery|November 12, 2015
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven NeuroblastomaNicole R Infarinato, Jin H Park, Kateryna Krytska, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 19, 2014
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjectsTheodore R Johnson, Weiwei Tan, Lance Goulet, et al.
Molecular Cancer Therapeutics|March 6, 2012
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitorHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Pageof 2